Accès gratuit
Med Sci (Paris)
Volume 27, Numéro 10, Octobre 2011
Page(s) 833 - 841
Section M/S Revues
Publié en ligne 21 octobre 2011
  1. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992 ; 46 : 473–484. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed] [Google Scholar]
  2. Abes R, Gelize E, Fridman WH, et al. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010 ; 116 : 926–934. [CrossRef] [PubMed] [Google Scholar]
  3. Taylor C, Hershman D, Shah N, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007 ; 13 : 5133–5143. [CrossRef] [PubMed] [Google Scholar]
  4. Bodmer A, Goetsch L, Favet L, et al. Anticorps et tumeurs solides : cibles établies et pistes prometteuses. Med Sci (Paris) 2009 ; 25 : 1090–1098. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors : a prognostic factor that should not be ignored. Oncogene 2010 ; 29 : 1093–1102. [CrossRef] [PubMed] [Google Scholar]
  6. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009 ; 21 : 233–240. [CrossRef] [PubMed] [Google Scholar]
  7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 ; 363 : 411–422. [CrossRef] [PubMed] [Google Scholar]
  8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011 ; 364 : 2119–2127. [CrossRef] [PubMed] [Google Scholar]
  9. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011 ; 29 : 2787–2794. [CrossRef] [PubMed] [Google Scholar]
  10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517–2526. [CrossRef] [PubMed] [Google Scholar]
  11. Atkins MB. Treatment selection for patients with metastatic renal cell carcinoma : identification of features favoring upfront IL-2-based immunotherapy. Med Oncol 2009 ; 26 (suppl 1): 18–22. [CrossRef] [PubMed] [Google Scholar]
  12. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001 ; 19 : 3477–3482. [PubMed] [Google Scholar]
  13. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [CrossRef] [PubMed] [Google Scholar]
  14. Haicheur N, Escudier B, Dorval T, et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000 ; 119 : 28–37. [CrossRef] [PubMed] [Google Scholar]
  15. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2. Based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996 ; 14 : 1697–1703. [PubMed] [Google Scholar]
  16. Derhovanessian E, Adams V, Hahnel K, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009 ; 125 : 1372–1379. [CrossRef] [PubMed] [Google Scholar]
  17. Marshall M, Ribas A, Huang B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. ASCO meeting abstracts, June 14th, 2010. J Clin Oncol 2010 ; 28 : 2609 (abstract). [CrossRef] [Google Scholar]
  18. Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010 ; 70 : 6171–6180. [CrossRef] [PubMed] [Google Scholar]
  19. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009 ; 27 : 2645–2652. [CrossRef] [PubMed] [Google Scholar]
  20. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010 ; 138 : 1429–1440. [CrossRef] [PubMed] [Google Scholar]
  21. Gajewski TF, Fuertes M, Spaapen R, et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2010 ; 23 : 286–292. [CrossRef] [PubMed] [Google Scholar]
  22. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005 ; 201 : 241–248. [CrossRef] [PubMed] [Google Scholar]
  23. Butterfield LH, Ribas A, Dissette VB, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003 ; 9 : 998–1008. [PubMed] [Google Scholar]
  24. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Exp Rev Vaccines 2008 ; 7 : 889–893. [CrossRef] [Google Scholar]
  25. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009 ; 361 : 1838–1847. [CrossRef] [PubMed] [Google Scholar]
  26. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008 ; 8 : 351–360. [CrossRef] [PubMed] [Google Scholar]
  27. Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009 ; 27 : 3036–3043. [CrossRef] [PubMed] [Google Scholar]
  28. Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme : pilot results leading to Phase III clinical development. Vaccine 2007 ; 25 (suppl 2): B61–B71. [CrossRef] [PubMed] [Google Scholar]
  29. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005 ; 23 : 7536–7545. [CrossRef] [PubMed] [Google Scholar]
  30. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010 ; 102 : 1388–1397. [CrossRef] [PubMed] [Google Scholar]
  31. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010 ; 28 : 1099–1105. [CrossRef] [PubMed] [Google Scholar]
  32. van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005 ; 23 : 9008–9021. [CrossRef] [PubMed] [Google Scholar]
  33. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 ; 354 : 709–718. [CrossRef] [PubMed] [Google Scholar]
  34. Bouwhuis MG, Ten Hagen TL, Suciu S, et al. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2010 ; 23 : 170–176. [CrossRef] [Google Scholar]
  35. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005 ; 23 : 6043–6053. [CrossRef] [PubMed] [Google Scholar]
  36. Nelson BH. CD20+ B cells : the other tumor-infiltrating lymphocytes. J Immunol 2010 ; 185 : 4977–4982. [CrossRef] [PubMed] [Google Scholar]
  37. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008 ; 3 : 735–744. [CrossRef] [PubMed] [Google Scholar]
  38. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008 ; 31 : 101–112. [CrossRef] [PubMed] [Google Scholar]
  39. Leibundgut-Landmann S, Osorio F, Brown GD, et al. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 2008 ; 112 : 4971–4980. [CrossRef] [PubMed] [Google Scholar]
  40. Berraondo P, Nouze C, Preville X, et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007 ; 67 : 8847–8855. [CrossRef] [PubMed] [Google Scholar]
  41. Adotevi O, Vingert B, Freyburger L, et al. B Subunit of Shiga toxin-based vaccines synergize with (alpha)-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007 ; 179 : 3371–3379. [PubMed] [Google Scholar]
  42. Vingert B, Adotevi O, Patin D, et al. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006 ; 36 : 1124–1135. [CrossRef] [PubMed] [Google Scholar]
  43. Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009 ; 119 : 2648–2662. [PubMed] [Google Scholar]
  44. Welters MJ, Kenter GG, van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010 ; 107 : 11895–11899. [CrossRef] [Google Scholar]
  45. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010 ; 207 : 2175–2186. [CrossRef] [PubMed] [Google Scholar]
  46. Derre L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010 ; 120 : 157–167. [CrossRef] [PubMed] [Google Scholar]
  47. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble alpha chain of interleukin-15 receptor : a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008 ; 68 : 3907–3914. [CrossRef] [PubMed] [Google Scholar]
  48. Cherfils-Vicini J, Platonova S, Gillard M, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010 ; 120 : 1285–1297. [CrossRef] [PubMed] [Google Scholar]
  49. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010 ; 140 : 798–804. [CrossRef] [PubMed] [Google Scholar]
  50. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008 ; 8 : 59–73. [CrossRef] [PubMed] [Google Scholar]
  51. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009 ; 114 : 589–595. [CrossRef] [PubMed] [Google Scholar]
  52. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999 ; 5 : 2963–2970. [PubMed] [Google Scholar]
  53. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010 ; 33 : 991–998. [CrossRef] [PubMed] [Google Scholar]
  54. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009 ; 15 : 2148–2157. [CrossRef] [PubMed] [Google Scholar]
  55. Huang KW, Wu HL, Lin HL, et al. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc Natl Acad Sci USA 2010 ; 107 : 14769–14774. [CrossRef] [PubMed] [Google Scholar]
  56. Abès R, Dutertre CA, Teillaud JL. Les anticorps : mieux les connaître pour mieux s’en servir. Med Sci (Paris) 2009 ; 25 : 1011–1019. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  57. Robert C, Mateus C. Anticorps anti–CTLA 4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  58. Apetoh L, Ghiringhelli F, Zitvogel L. La calréticuline détermine l’immunogénicité de la chimiothérapie et de la radiothérapie antitumorales. Med Sci (Paris) 2007 ; 23 : 257–258. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  59. Rousseaux S, Reynoird N, Gaucher J, Khochbin S. L’intrusion des régulateurs de l’épigénome mâle dans les cellules somatiques cancéreuses. Med Sci (Paris) 2008 ; 24 : 735–741. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  60. Olive D, le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du système immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.